Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The investigators design a phase IIB clinical study to explore the efficacy and safety of
lenvatinib plus pembrolizumab as a second-line treatment in patients with advanced
hepatobiliary malignant tumors and to analyze potential biomarkers of therapeutic response.